RNS Number: 1063Y Ondine Biomedical Inc. 04 September 2025

TR-1: Standard form for notification of major holdings

TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
CA68234M2058
Issuer Name
ONDINE BIOMEDICAL INC
UK or Non-UK Issuer
Non-UK
2. Reason for Notification
Other
Comments
Placement of shares
3. Details of person subject to the notification obligation
Name
M&G Plc
City of registered office (if applicable)
London
Country of registered office (if applicable)
United Kingdom
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above
City of registered office (if applicable)
Country of registered office (if applicable)
5. Date on which the threshold was crossed or reached
03-Sep-2025
5. Date on which Issuer notified
04-Sep-2025
7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the				
date on which threshold was	12.974380	0.000000	12.974380	67254901

crossed or reached				
Position of previous notification (if applicable)	9.182066	0.000000	9.182066	

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)		% of indirect voting rights (DTR5.2.1)
CA68234M2058		67254901		12.974380
Sub Total 8.A	67254901		12.974380	%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1				

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Exercise/conversion period	Number of voting rights	% of voting rights
Sub Total 8.B2			

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
M&G Plc	M&G Plc (Parent company)	12.974380%		12.974380%
M&G Plc	M&G Group Regulated Entity Holding Company Limited (wholly owned subsidiary of M&G Plc)	12.974380%		12.974380%
M&G Plc	M&G Group Limited (wholly owned subsidiary of M&G Group Regulated Entity Holding Company Limited)	12.974380%		12.974380%
	M&G FA			

M&G Plc	Limited (wholly owned subsidiary of M&G Group Limited)	12.974380%	12.974380%
M&G Plc	M&G Investment Management Limited (wholly owned subsidiary of M&G FA Limited)	12.974380%	12.974380%

l l]
10. In case of pr	oxy voting			
Name of the pr	oxy holder			
The number an	d % of votin	g rights held		
The date until v	hich the vot	ing rights will	be held	
11. Additional In	formation			
12. Date of Com	pletion			
04-Sep-2025				
13. Place Of Con	pletion			
London, United I	Kingdom			

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLSSFFMLEISEEU